6 Hedge Fund Favorite Stocks Likely to Move Big on Upcoming Readout

Our Q2 Hedge Fund data is now updated! A few favorite stocks are lining up for major readouts in Q3–Q4, and some are likely to move big.

Below are 6 key catalysts we’re watching closely. 📈 📉

$MLTX 

Sonelokimab / Hidradenitis Suppurativa / Phase 3

» Potential for a highly differentiated, “gold standard” therapy in HS

» Achieved highest responses to date in HS

» Ph2 MIRA trial in HS was designed as a pivotal study

Ph2 results recap 👇

$CRNX 

Paltusotine / Acromegaly / PDUFA

» Ph3 studies show improved acromegaly symptom control

» Met primary and all secondary endpoints

→ 83% of participants on Paltusotine maintained IGF-1 ≤1.0 xULN

→ Maintained Control of IGF-1

→ Well-tolerated, no new safety signals

Ph3 PATHFINDR key findings 👇

$PRAX

Ulixacaltamide / Essential Tremor / Phase 3

» Innovative Ph3 program underway

» Essential1 Ph2b study showed mADL & ADL improvement vs placebo

» Consistent effect vs placebo across ADL Scored Items

» Higher overall improvement in status vs placebo

Ph3 design and Ph2 results 👇

$MTSR

MET-097i / Obesity / Phase 2b

» Longest-acting NuSH peptide in development

→ Half-life potentially enables monthly dosing and titration-free, intermittent dosing

» 12-wk wt loss consistent with approved & development-stage dual agonists

» GI AEs mostly mild; titrated dosing particularly well-tolerated

Ph1/2 program overview & results 👇

$GPCR 

Aleniglipron (GSBR-1290) / Obesity / Phase 2b

» Potential Best-in-class oral GLP-1R agonist

→ Efficacy: 6.2 to 6.9% placebo-adjusted wt loss at 12 wks

→ Tolerability: 5 to 11% AE-related study discontinuations\

→ Safety: Large safety window

Ph2a results & Ph2 ACCESS & ACCESS II study design 👇

$COGT

Bezuclastinib / Gastrointestinal Stromal Tumors / Phase 3

» 2nd-line GIST: No new drugs approved since 2006

» PEAK result of ~3 mos advantage over sunitinib expected to be clinically meaningful for GIST patients

Ph3 overview and initial results 👇

#MLTX #CRNX #PRAX #MTSR #GPCR #COGT

This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.

Article history:

First published 08/20/25 JD, AV, DG, EJV